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tradiol (E2) exerts inhibitory actions on the nitric oxide pathway in rat
adult pituitary glands. Previously, we reported that in vivo E2 acute
treatment had opposite effects on soluble guanylyl cyclase (sGC)
subunits, increasing 1- and decreasing 1-subunit protein and mRNA
expression and decreasing sGC activity in immature rats. Here we
studied the E2 effect on sGC protein and mRNA expression in anterior
pituitary gland from adult female rats to address whether the matura-
tion of the hypothalamus-pituitary axis influences its effects and to
corroborate whether these effects occur in physiological conditions
such as during estrous cycle. E2 administration causes the same effect
on sGC as seen in immature rats, and these effects are estrogen
receptor dependent. These results suggest that E2 is the main effector
of these changes. Since the sGC -subunit increases while the sGC
activity decreases, we studied if other less active isoforms of the sGC
-subunit are expressed. Here we show for the first time that sGC2
and sGC2 inhibitory (2i) isoforms are expressed in this gland, but
only sGC2i mRNA increased after E2 acute treatment. Finally, to test
whether E2 effects take place under a physiological condition, sGC
subunit expression was monitored over estrous cycle. sGC1, -1, and
-2i fluctuate along estrous cycle, and these changes are directly
related with E2 level fluctuations rather than to NO level variations.
These findings show that E2 physiologically regulates sGC expression
and highlight a novel mechanism by which E2 downregulates sGC
activity in rat anterior pituitary gland.
estrogen; soluble guanylyl cyclase; inhibitory subunit
THE MAIN ESTROGENIC HORMONE 17-estradiol (E2) plays impor-
tant regulatory roles in a broad variety of biological processes,
acting mainly on reproductive tissues, bone, liver, pituitary,
and brain (9, 25).
Nitric oxide (NO) is a signaling molecule that freely diffuses
across cellular membranes where it binds to its main intracel-
lular receptor, soluble guanylyl cyclase (sGC). This enzyme
catalyzes the formation of cGMP from GTP. Subsequently,
targets of cGMP such as cGMP-dependent protein kinases,
cyclic nucleotide phosphodiesterases, and cyclic nucleotide-
sensitive ion channels are activated to continue the signal
transduction (15, 18).
sGC is an heterodimeric enzyme and is comprised of two
subunits,  and , of which four types exist (1, 2, 1, and
2). Both -isoforms form a functional enzyme with the
1-subunit, although the 11 is the most abundant and widely
expressed heterodimer, showing the greater activity (12, 13).
The 2 is expressed in a more restricted pattern: in human
tissues, it is present mainly in spleen, placenta, brain, and
uterus; in rat, it was found in fetal brain (3). Furthermore, an
inhibitory 2-subunit (2i) and many splicing variants of both
isoforms of variable activity have also been identified (1, 22).
Reports indicate that E2 regulates the NO/sGC/cGMP path-
way and the levels of NO and cGMP in many tissues. Several
studies (21, 24) sustain an inhibitory role of E2 on the NO
pathway in pituitary gland. Pituitary glands from ovariecto-
mized rats show increased NO synthase activity and mRNA
and protein levels, whereas E2 treatment reverts this condition.
These E2 effects were only observed after in vivo treatment,
and it has been suggested that they are indirect. In addition, it
has been reported that E2 affects sGC expression and activity in
uterus, PC12 cells, and hypothalamus (8, 10, 14). Previous
studies from our laboratory (4) show that acute E2 treatment
exerts an inhibitory effect on sGC by downregulating the
sGC1 subunit and sGC activity but increases sGC1 expres-
sion in anterior pituitary gland from immature rats. E2 effects
on anterior pituitary sGC were observed such after in vivo as
in vitro treatment, suggesting a direct effect of E2 on sGC
regulation and a differential and independent regulation of both
subunits. Previous evidence (4, 7) further sustains that under
certain conditions 1 and 1 can be independently regulated.
Taking into account preceding results, the aim of this work
was to investigate whether E2 affects sGC subunit expression
and activity on pituitary gland from adult rats and to corrobo-
rate whether these effects occur in physiological conditions
such as during estrous cycle. Besides, since the sGC -subunit
increases while sGC activity decreases, we studied the expres-
sion of other less active isoforms of the sGC -subunit in the
anterior pituitary gland and whether they are regulated by E2.
To this end, we studied the in vivo effect of exogenous or
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tin, PMSF, DTT, and diaminobenzidine were obtained from
Alexis-US Biological (Swampscott, MA). Bradford reagent was pur-
chased from Bio-Rad (Hercules, CA). Propylene glycol and hydrogen
peroxide were from Cicarelli (Buenos Aires, Argentina). GoTaq DNA
polimerase was provided by Promega (Madison, WI). TRIzol and
molecular biology reagents were from Invitrogen (Carlsbad, CA).
Media and reagents for cell culture were purchased from GIBCO
(Rockville, MD), except for the FBS that was obtained from GBO
(Buenos Aires, Argentina). Otherwise indicated, all other reagents and
antibodies were obtained from Sigma-Aldrich (Buenos Aires, Argen-
tina).
Animals and treatments
Adult female Wistar rats (180–200 g) were used. Animals were
kept with controlled conditions of light (12:12-h light-dark cycle) and
temperature (21–24°C). Food and water were supplied ad libitum. All
procedures were in accordance with the National Institutes of Health’s
Guide for the Care and Use of Laboratory Animals.
For E2 acute effects experiments, rats were injected subcutaneously
in the periscapular region with 40 g/kg body wt E2 or with vehicle
alone (propylene glycol) and killed over a time course. When re-
quired, animals were injected intraperitoneally with 2 mg/kg ICI
182,780 30 min before 40 g/kg E2 administration.
Intact rats were monitored by daily (0800-0900) vaginal smears
over three consecutive cycles. Animals at random stages of estrous
cycle or at proestrus, estrus, or diestrus were killed by decapitation at
1700.
Ovariectomy
Rats were ovariectomized under ketamine (75 mg/kg; Holliday-
Scott, Buenos Aires, Argentina) and xylacine (10 mg/kg; König,
Buenos Aires, Argentina) anesthesia 14 days before the experiments.
Sham-operated rats were used as controls.
Cell culture
Primary cell culture was prepared from anterior pituitary glands
from ovariectomized or sham rats killed at 14 days postsurgery.
Anterior pituitary glands from each condition were pooled for each
cell culture. Cells were obtained by enzymatic (trypsin/DNAse) and
mechanical dispersion (extrusion through a Pasteur pipette). Cell
viability was assessed by the trypan blue exclusion method. Dispersed
cells were seeded onto tissue culture plates and stabilized for 48 h
(37°C, 5% CO2 in air) in phenol red-free DMEM supplemented with
10% charcoal stripped FBS, 10 l/ml MEM amino acids, 2 mM
glutamine, 5.6 g/ml amphotericin B, and 25 g/ml gentamicin.
Cell treatment
After the stabilization period, the medium was changed for fresh
medium and cells were incubated during 6 h (37 °C, 5% CO2 in air)
with or without 0.5 mM DETANONOate. After treatment, RNA
isolation from each condition was carried out.
Immunoblot analysis
Anterior pituitary glands were removed and sonicated in lysis
buffer containing 10 mM HEPES pH 7.4, 150 mM NaCl, 10 mM
EDTA, 100 M leupeptin, 350 M pepstatin, 0.5 mM PMSF, and 0.2
mM DTT. Sonicates were centrifuged for 20 min at 10,000 g, and the
soluble fraction was used in the immunoblot analysis. Protein content
from the supernatants was measured by Bradford reagent, using BSA
as a standard. Twenty to thirty micrograms of total protein from each
sample were boiled for 5 min in Laemmli sample buffer and were
fractioned on 10% SDS-PAGE. Resolved proteins were transferred to
polyvinylidene difluoride membranes and blocked for 2 d at 4°C in
blocking buffer (TBS-0.05% Tween 20 and 6% nonfat dry milk).
Then, membranes were coincubated overnight at 4°C with rabbit
antisera anti-GC1 (1:1,750) or 1 (1:700) subunits and anti-actin
(1:1,000) in blocking buffer. Then blots were washed and incubated
for 1 h at room temperature with horseradish-peroxidase conjugated
goat anti-rabbit IgG (1:2,000), followed by detection of immunoreac-
tivity with diaminobenzidine solution containing 0.01% hydrogen
peroxide.
RT-PCR and semiquantitative PCR
RNA isolation. Tissues were removed and immediately homoge-
nized with TRIzol reagent. After isolation, total RNA from tissues
was spectrophotometrically quantified at 260 nm. RNA integrity was
checked in formaldehyde/formamide gel electrophoresis.
RT and PCR reactions. First-strand cDNA was synthesized with
Moloney murine leukemia virus RT in RT buffer containing 5.5 mM
MgCl2, 0.5 mM dNTP, 2.5 M random hexamers, and 3.125 U/l
Moloney murine leukemia virus RT. Reactions were done in a final
volume of 12 l containing 1 g RNA. The RT reaction was run at
37°C for 50 min, and RT was inactivated by heating the samples at
70°C for 15 min before the PCR reactions. To check for genomic
contamination, the same procedure was performed on samples in a
reaction solution lacking RT.
Specific primers for both subunits of sGC were designed from
published sequences (23) with Oligo Perfect designer software (In-
vitrogen) and are detailed in Table 1. The amplified products spanned
from nucleotide position base 1,971 to 2,054 in the C-terminal region
of sGC1, from 714–823 in the N-terminal region of sGC1, from
1,530–1,929 in the C-terminal region of sGC2, and from within the
in-frame insert to 275 bp to the 3-end of sGC2i (1). -Actin was
used as an endogenous control. Actin primers were designed to detect
amplification of DNA contamination. Then, samples were thermo-
cycled for PCR amplification (Mastercycler; Eppendorf, Hamburg,
Germany). The reaction mixture contained GoTaq PCR buffer, 1.5
mM MgCl2, 200 M of each dNTP, 0.625 U GoTaq polymerase, and
300 nM of each primer. RT-PCR methods were utilized to determine
relative changes in mRNA expression. Reactions were subjected to a
varying number (n  16–40) of cycles of PCR amplification (melting
phase 94°C for 30 s, annealing 55°C for 30 s, and extension 72°C for
1 min) to find out the optimum cycle number within the linear range
for PCR amplification. Amplified products collected at various cycles
were analyzed by electrophoresis in 1.5% agarose-ethidium bromide
gels, and the optimum cycle number resulted in 24 cycles for -actin,
28 cycles for sGC1 and 1, and 40 cycles for sGC2 and sGC2i.
Analysis of semiquantitative PCR and immunoblot data
The intensities of PCR products and immunoblot signals were
determined by digital image analysis using the Gel Pro analyzer
Table 1. Primers used for semiquantitative RT-PCR assays
Gene Primer Product Size
sGC1
Forward 5-ACACAATATGCATCTCCGATGG-3 83 bp
Reverse 5-GCTCTCTATACTCGCTTTGACCAA-3
sGC1
Forward 5-CCCGTGGAAACTGATGTCAA-3 109 bp
Reverse 5-CGGGACCTAGTAGTCACGCA-3
sGC2
Forward 5-GCGACTGTCTACCCCGTTTGTGAT-3 399 bp
Reverse 5-CTGTACTTGCTGCCCTTGCCATAA-3
sGC2i
Forward 5-TTTTCTCCTTTCCTGTTTCCATCC-3 275 bp
Reverse 5-ACGAGACCGCGGAATGAATG-3
-Actin
Forward 5-ACCACAGCTGAGAGGGAAATCG-3 276 bp
Reverse 5-AGAGGTCTTTACGGATGTCAACG-3
sGC, soluble guanylyl cyclase; i, inhibitory isoform.
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(Media Cybernetics, Silver Spring, MD) software for Windows. To
allow statistical comparison of results from different experiments,
sGC subunits levels were normalized to the value of the -actin
amplified band in each lane or to the actin immunoreactive band,
respectively.
Intracellular cGMP determination
Anterior pituitary glands were quickly removed and placed on dry
ice. Subsequently, they were sonicated in warm 50 mM sodium
acetate pH 6.2, boiled for 10 min, and centrifuged at 10,000 g for 10
min. Supernatants were stored at 70°C until cGMP determination.
Cyclic GMP was assayed as previously described (2) by specific RIA
using rabbit anti-cGMP polyclonal antiserum and acetylated cGMP as
standard. Total protein content in the pellets was measured as de-
scribed above.
Statistical analysis
Results are expressed as means  SE and were evaluated by
one-way ANOVA followed by Dunnett’s, Tukey’s, or Student’s t-test,
depending on the experimental design. Differences between groups
were considered significant if P  0.05. Results were confirmed by at
least three independent experiments.
RESULTS
E2 Administration Increased sGC1 and Decreased sGC1
Protein and mRNA Expression in Anterior Pituitary Glands
of Adult Female Rats, Decreasing cGMP Production
To Identify Whether the Maturation of the Hypothalamus-
pituitary axis influences E2 effects on sGC subunits, we studied
the influence of a physiological dose of E2 (4, 14) on sGC
subunit expression in adult female rats. Rats at random estral
stages (n  5 per group) received a single dose of 109 M E2
and were killed over a time course. As seen previously in
immature rats (4), in vivo administration of E2 resulted in an
increase of sGC1 levels and, concomitantly, a decrease in
sGC1 protein levels. These effects became evident as soon as
4 h after E2 administration and were maximal at 8 h (relative
units as percentage of control, 8-h E2; sGC1: 143  11 and
sGC1: 79  8; P  0.05, ANOVA followed by Dunnett’s
test). Protein levels of both subunits tended to return to control
values after 12–16 h post-E2 injection (data not shown). Since
these changes in protein expression could respond to altered
mRNA synthesis, we evaluated then the action of E2 on sGC1
and sGC1 mRNA expression by semiquantitative PCR. At 4-
and 8-h post-E2 injection, sGC1 mRNA was significantly
augmented respect to control values (Fig. 1). At the same time
points, sGC1 mRNA levels were diminished, consistent with
the observed at protein level. These findings indicate that the
differences observed at the protein level are consequence of
effects at the transcription level.
Given that both subunits are required at 1:1 stoichiometry to
have cGMP-producing activity, cGMP production was mea-
sured at different times. sGC activity was significantly reduced
after 8 h of treatment with E2 [concentration of GMP (fmol/mg
prot); means  SE; control: 160  23, E2 4 h: 220  38, and
E2 8 h: 98  21; P  0.05 vs. control, ANOVA followed by
Dunnett’s test; n  3], when the difference between subunit
expression became maximal (data not shown). These results
suggest that, independently of sGC1 subunit increase, E2-
mediated downregulation of 1 would be enough to decrease
cGMP in the pituitary.
E2 effects are estrogen receptor dependent
Next, to test if the actions of E2 on sGC subunits levels were
specific, rats were injected with the pure estrogen receptor
(ER) antagonist ICI 182,780 (2 mg/kg ip) 30 min before E2
administration and killed after 8 h. The antagonist had no effect
by itself, but when coadministered with E2, it was able to
completely avoid E2 effects on both sGC subunit protein levels
(Fig. 2). This observation indicates that the E2 effects on sGC
expression are mediated by ER activation.
E2 acute treatment increases the expression of the inhibitory
subunit 2i
It is known that other isoforms of sGC are expressed in
different tissues. To date, the presence of these isoforms was
not reported in pituitary gland. In our case, the augment
registered in sGC1 protein as well as in mRNA could be due
to an increase in 1 and/or to other less active or inhibitory
isoforms of sGC. In the present work, the anti-sGC1 anti-
body utilized for immunoblot studies, as well as the primers
used to amplify sGC1 mRNA, was directed to the C-terminal
sequence of rat sGC1 and it cannot differentiate among sGC
species, since all of them include this sequence. To examine if
these subunits are expressed in this tissue, we performed
RT-PCR to detect sGC2 and 2i, using specific primers and
liver and kidney or spleen as control tissues, respectively. Here
we show for the first time that sGC2 and 2i are expressed in
anterior pituitary gland (Fig. 3A). Then, to investigate if their
expression was modified by E2 treatment, rats were treated
with a single dose of E2 and killed after 6 h. E2 treatment did
not modify 2 mRNA expression respect to control, but 2i
mRNA levels were dramatically increased (relative units as
percentage of control; sGC2 control: 100  24; E2 8 h: 94 
30; sGC2i control: 100  18; and E2 8 h: 1,730  105; P 
0.001, Dunnett’s test; n  3; Fig. 3B). Again, to verify if this
effect was E2 specific, rats were injected intraperitoneally with
2 mg/kg ICI 182,780 30 min before E2 subcutaneous admin-
istration, and killed over 8 h. The inhibitor was able to fully
Fig. 1. Acute E2 treatment increases 1 soluble guanylyl cyclase (sGC) but
decreases 1 sGC mRNA expression in rat anterior pituitary gland. Adult intact
rats at random stages of estrous cycle (n  5 per group) were injected
subcutaneous with 40 g/kg body wt E2 and killed after 8 h. Top: represen-
tative semiquantitative PCR. Bottom: average densitometric values. Bars are
means  SE of the densitometric values of sGC1 (open bars) and sGC1
(solid bars) mRNA densitometric values normalized to actin, as percentage of
control (n  5). *P  0.05, **P  0.01 vs. control, ANOVA followed by
Dunnett’s test.
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abolish 2i expression increase and had no effect per se on
sGC2i (Fig. 3C). Thus the augmented sGC expression may
reflect 1-increased levels but also an augmented 2i expres-
sion. These findings suggest that both 1 downregulation and
2i-augmented expression could contribute to the acute inhib-
itory effect of E2 on sGC.
sGC subunit expression levels are variable through
estrous cycle
Taking into account the acute E2 actions on sGC expression
and activity and to examine whether these effects occur under
physiological conditions, we studied the changes on sGC
through estrous cycle, a condition where E2 and also gonado-
trophins, prolactin, and other gonadal steroids undergo rapid,
dramatic changes. To this end, rats were killed on the afternoon
(1700) of each stage of the estrous cycle and sGC protein levels
were analyzed by Western blot. Protein levels of sGC1
showed a significant increase through the cycle from proestrus
to diestrus (Fig. 4A). sGC1 protein levels, which were higher
than sGC1 on the afternoon of proestrus, did not change
during estrus but significantly decreased at diestrus. Similar
results were observed when sGC1 and 1 mRNA expression
was evaluated by RT-PCR (data not shown). These findings
show that sGC subunits levels independently fluctuate in vivo
during estrous cycle. These individual variations of sGC sub-
unit expression are consequence of hormonal changes taking
place during estrous cycle, because in male rats and in ovari-
ectomized rats both subunits show similar mRNA levels (rel-
ative units expressed as means  SE; n  3; male sGC1:
1.41  0.15 and sGC1: 1.54  0.2; and 14-day ovariecto-
mized sGC1: 1.43  0.42 and sGC1: 1.61  0.23).
sGC2i expression levels are variable through the
estrous cycle
Bearing in mind our findings showing that sGC1 expres-
sion increases over the cycle in spite of the decrease in cGMP
production, the sGC2i contribution to global expression was
addressed. In accordance with the enhanced sGC activity on
proestrus, 2i mRNA expression was the lowest at this stage
(Fig. 4B). On estrus and diestrus, 2i expression was signifi-
cantly augmented, which correlates with a lesser cGMP pro-
duction. Altogether, the difference between sGC subunit ex-
pression according to the stage of the estrous cycle in which the
animals were killed suggests the cyclicity of the response.
Role of NO on sGC subunit expression
NOS I protein and activity are strikingly upregulated on the
afternoon of proestrus, and both return to basal levels after the
afternoon of estrous, remaining low on diestrus I and II. cGMP
production strongly correlates with NOS I upregulation (17).
To determine if the changes seen in sGC subunit protein levels
were due to changes in NO levels, we studied the in vitro effect
of a short-time NO and E2 exposition on sGC protein expres-
sion. Pituitary cell cultures from intact adult female rats were
incubated with 0.1 mM DETANONOate, a NO donor, or 109
M E2 for 6 h, and sGC1 and 1 expression was evaluated by
Western blot. NO treatment upregulated both subunits in a
Fig. 2. E2 actions on sGC protein expression are abolished by pure anti-
estrogenic ICI 182,780 pretreatment in rat anterior pituitary gland. Adult intact
rats at random stages of estrous cycle (n  5 per group) were injected
subcutaneous with 2 mg/kg ICI 182,780 (ICI) 30 min before 40 g/kg body wt
E2 injection and killed after 8 h. Top: representative Western blot. Bot-
tom: average densitometric values. Bars represent media  SE of the densi-
tometric values of sGC1 (open bars) and sGC1 (solid bars) protein levels
normalized to actin, as percentage of control (n  3). *P  0.05, **P  0.01
vs. respective controls; 	P  0.05, 		P  0.01 vs. E2, ANOVA followed by
Dunnett’s test.
Fig. 3. Other isoforms of sGC are expressed normally in rat anterior pituitary
gland. A: representative PCR showing the presence of sGC2 and 2i mRNAs
in anterior pituitary. Liver, kidney, and spleen were used as respective control
tissues. B: acute E2 exposition increases the mRNA expression of the dominant
negative isoform sGC2i. Animals were injected with 40 g/kg body wt E2
and killed after 8 h. C: role of ER in sGC2i-augmented expression. Adult
intact rats at random stages of estrous cycle (n  3 per group) were injected
intraperitoneally with 2 mg/kg ICI 182,780 30 min before 40 g/kg body wt
E2 injection and killed after 8 h. Bars are means  SE of the densitometric
values of sGCi mRNA normalized to actin, as percentage of control (n  3).
*P  0.05 vs control; 	P  0.05 vs. E2, ANOVA followed by Tukey’s test.
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similar fashion (Fig. 5A) while E2 treatment increased 1 but
decreased 1 expression (Fig. 5B). In addition, sGC1 and -1
expression was studied in the anterior pituitary glands of
14-day ovariectomized rats when NOS I protein and activity
were markedly upregulated. At this condition, the results were
similar to those with the NO donor in vitro (relative units as
percentage of control; sGC1: 120.7  7.5 and sGC1:
126  10.7; P  0.05, ANOVA followed by Dunnett’s test;
n  3). Thus short-time in vitro NO treatment or chronic
in vivo NO increase did not mimic the effect of E2 in vitro
or those seen in vivo during estrous cycle on sGC subunits.
These results suggest again that the imbalance of sGC
subunit expression is likely due to hormonal fluctuations
rather than to NO.
DISCUSSION
Here we have shown that E2 causes the same effect on sGC
subunits in adult and juvenile female animals, suggesting that
these effects are distinctive of E2 and independent of the
hormonal fluctuation during the maturation of the reproductive
axis. In vivo E2 acute treatment exerted opposite actions on
both sGC subunits, increasing sGC1 mRNA and protein
levels and, simultaneously, decreasing sGC1 mRNA and
protein levels. These effects were E2 specific and ER depen-
dent. Our results also demonstrate that - and -subunit levels
are independently modified. Different authors have previously
reported that under certain conditions - and -subunits can be
individually regulated. A complete loss of the 1-subunit in
aortic smooth muscle cells from old rats has been found, while
the -subunit is still present (7). In developing rat brain, only
sGC mRNA is expressed, while sGC1 is totally absent (26),
raising interesting questions regarding the independent func-
tions of each subunit.
We have demonstrated that E2 acute treatment enhanced 1
mRNA and protein expression but decreased sGC activity. It is
known that fully active sGC requires - and -subunits in a
strict 1:1 stoichiometry, and, even considering that 1 expres-
sion was increased, sGC1 downregulation would be enough
to reduce sGC global activity. However, the higher expression
of GC could be due, at least in part, to an increased expres-
sion of other -isoforms with less activity. In the present work,
we have demonstrated for the first time that sGC2 and sGC2i
isoforms are expressed in anterior pituitary gland and that after
E2 stimulus sGC2i expression (but not 2) is augmented. The
Fig. 4. sGC subunit expression fluctuates over estrous cycle. Rats (n  3 per
group) were killed at 1700 on proestrus, estrus, or diestrus. A, top: a repre-
sentative Western blot; bottom: average densitometric values. Bars are
means  SE of sGC1 (open bars) and sGC1 (solid bars) protein values
normalized to actin (n  3). *P  0.05 vs. estrus, ANOVA followed by
Tukey’s test. B, top: a representative PCR of sGC2i; bottom: average
densitometric values. Bars are means  SE of sGC2i mRNA levels normal-
ized to actin (n  3). *P  0.05 vs. estrus and diestrus, ANOVA followed by
Tukey’s test.
Fig. 5. Short-time nitric oxide exposure upregulated sGC expression, while E2
acute expression differentially affects sGC subunits in vitro. A: primary
pituitary cell cultures from adult intact rats at random stages of estrous cycle
were incubated with 0.5 mM DETANONOate, a nitric oxide donor, or with
culture medium alone (control) for 6 h. Top: representative Western blot.
Bottom: average densitometric values. Bars are media  SE of sGC1 (open
bars) or sGC1 (solid bars) protein levels normalized to actin, as percentage of
control (n  5). B: primary pituitary cell cultures from intact, adult rats were
incubated with 109 M E2 or with culture medim alone (control) for 6 h.
Top: representative Western blot. Bottom: average densitometric values. Bars
are means  SE of sGC1 (open bars) or sGC1 (solid bars) protein levels
normalized to actin, as percentage of control (n  3). *P  0.05 vs. respective
control, Student’s t-test.
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fact that the inhibitory  isoform could collaborate to E2
transient sGC inhibition indicates again that E2 is acting
through multiple pathways. Therefore, our results show that E2
not only decreases sGC1 expression but also stimulates
sGC2i expression and by these ways participates in sGC
activity downregulation.
The estrous cycle is a physiological event in which mainly
E2 levels, among other hormones, suffer strong changes (27).
We studied the expression of both sGC subunits during the
estrous cycle to address whether the changes in E2 levels are
reflected in the expression pattern of sGC in anterior pituitary
gland. Results from this work show that sGC- and -subunits
levels fluctuate through estrous cycle, further supporting a
correlation between E2 level changes and sGC expression
pattern. On diestrus, when E2 levels are rising and NO pro-
duction is at baseline levels, the expression of sGC1 is the
lowest of the entire cycle and, conversely, sGC1 expression is
maximal. Later, on the afternoon of proestrus, when serum E2
levels have drastically fallen and NO production is high,
sGC1 expression decreases, while a marked increase in
sGC1 expression is observed. However, the changes in sGC
subunit expression are not identical to that obtained after E2
acute administration; there is a shifting towards diestrus where
the maximal expression of 1 was observed. It is possible that
the slow but continuous increase in serum E2 levels, beginning
on diestrus I, would be enough to cause the differential changes
in the sGC subunits on diestrus.
Our results show that E2 treatment enhances sGC expres-
sion, including an augment in 2i. However, the proportion of
2i vs. 1 expression is very low. Why does E2 augment sGC1
expression if it would not be involved in sGC enzyme consti-
tution? There is some evidence that strongly suggests that the
sGC1 subunit can be individually involved in other processes,
independently of cGMP production. In advanced prostate can-
cer, sGC1 levels are highly correlated with proliferation (5).
E2 as a mitogenic factor, as well as a proapoptotic stimulus,
drives changes in pituitary cell poblation (11, 16, 20). sGC1
levels and timing of pituitary cell proliferation seem to be
correlated. sGC1 expression raises on estrus and diestrus,
while proliferation events are taking place, and remains low on
proestrus, when the highest levels of apoptotic cells are de-
tected (6, 19, 28). Thus the putative role of 1 in anterior
pituitary cell renewal opens a very attractive landscape that is
now under investigation.
NO modifies sGC expression on various tissues (15), and
NOS expression and activity in anterior pituitary are variable
and susceptible of regulation during estrous cycle (17). Here
we show that both short- and long-time NO exposition upregu-
lated both sGC subunits at the same extent. Therefore, NO
seems not to be involved in the differential changes of the sGC
subunit expression during the estrous cycle.
In summary, we provide evidence that sGC activity is
downregulated and its subunits are independently affected
upon stimulus with exogenous E2 and during the estrous cycle
in the rat anterior pituitary gland. These effects appear to be
independent of the hypothalamic-pituitary-gonadal axis matu-
ration. The expression of other less active or inhibitory sGC
isoforms provides a new potential regulation point in sGC
activity. The study of the roles of each subunit of sGC in other
processes, in addition to the classical cGMP-producing func-
tion, will raise new perspectives and novel pathways to a
well-known enzyme.
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